Top

Published in:

Open Access 01-12-2020 | Bisphosphonate | Review

Supportive medication in cancer during pregnancy

Authors: Flora Zagouri, Nikolaos Dedes, Alkistis Papatheodoridi, Michael Liontos, Meletios Athanasios Dimopoulos

Published in: BMC Pregnancy and Childbirth | Issue 1/2020

Abstract

While pregnancy-related malignancies are quite rare, their incidence is increasing and thus affecting more and more women nowadays. Their management, however, with both chemotherapy and supportive agents remains quite challenging and it seems crucial to define the optimal treatment for this special population. Concerning supportive medication, it is clinically significant to determine whether commonly used agents, including Granulocyte Colony-Stimulating Factors, Erythropoiesis-stimulating agents, Bisphosphonates, Anticoagulation agents, Antiemetics and Glucocorticoids are indeed effective in ameliorating chemotherapy side effects. Meanwhile, it is of great importance that the administration of any of these agents is safe for both mother and fetus. This review aims to provide a précis of the current literature regarding both safety and efficacy of all categories of supportive medication during pregnancy.

Zagouri F, Psaltopoulou T, Dimitrakakis C, Bartsch R, Dimopoulos MA. Challenges in managing breast cancer during pregnancy. J Thorac Dis. 2013;5(SUPPL.1):1–6.

Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019.

Eastwood-Wilshere N, Turner J, Oliveira N, Morton A. Cancer in Pregnancy. Asia Pac J Clin Oncol. 2019;(January):1–13.

Hepner A, Negrini D, Hase EA, Exman P, Testa L, Trinconi AF, et al. Cancer During Pregnancy: The Oncologist Overview. World J Oncol. 2019;10(1):28–34.PubMedPubMedCentralCrossRef

Avivi I, Farbstein D, Brenner B, Horowitz NA. Non-Hodgkin lymphomas in pregnancy: Tackling therapeutic quandaries. Blood Rev [Internet]. 2014;28(5):213–20. Available from: https://doi.org/10.1016/j.blre.2014.06.004.

Food and Drug Administration (FDA). Medication Guide (Darbepoetin alfa). 2011; Available from: www.fda.gov/medwatch.

Zeidler C, Grote UAH, Nickel A, Brand B, Carlsson G, Cortesão E, et al. Outcome and management of pregnancies in severe chronic neutropenia patients by the European branch of the severe chronic neutropenia international registry. Haematologica. 2014;99(8):1395–402.PubMedPubMedCentralCrossRef

Boxer LA, Bolyard AA, Kelley ML, Marrero TM, Phan L, Bond JM, et al. Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. Obstet Gynecol. 2015;125(1):197–203.PubMedPubMedCentralCrossRef

Exman P, Freret TS, Economy KE, Chen WY, Parsons HA, Lin NU, et al. Abstract P1-17-02: Outcomes and safety of paclitaxel and granulocyte-colony stimulating factor (GCSF) in breast cancer in pregnancy (BCP) - A multi-institutional retrospective analysis. Cancer Res [Internet]. 2019 Feb 15;79(4 Supplement):P1-17-02 LP-P1-17-02. Available from: http://cancerres.aacrjournals.org/content/79/4_Supplement/P1-17-02.abstract.

10.

Gurevich - Shapiro A, Avivi I. Current treatment of lymphoma in pregnancy. Expert Rev Hematol [Internet]. 2019;12(6):449–59. Available from: https://doi.org/10.1080/17474086.2019.1615878.

11.

Cardonick E, Irfan F, Torres N. The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment. J Cancer Ther. 2012;03(02):157–61.CrossRef

12.

Eapen A, Joing M, Kwon P, Tong J, Maneta E, De Santo C, et al. Recombinant human granulocyte- colony stimulating factor in women with unexplained recurrent pregnancy losses: A randomized clinical trial. Hum Reprod. 2019;34(3):424–32.PubMedPubMedCentralCrossRef

13.

Scarpellini F, Sbracia M. Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: A randomised controlled trial. Hum Reprod. 2009;24(11):2703–8.PubMedCrossRef

14.

Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(August):v111–8.PubMedCrossRef

15.

Cyganek A, Pietrzak B, Kociszewska-Najman B, Sanko-Resmer J, Paczek L, Wielgos M. Anemia treatment with erythropoietin in pregnant renal recipients. Transplant Proc [Internet]. 2011;43(8):2970–2. Available from: https://doi.org/10.1016/j.transproceed.2011.08.054.

16.

Hiller JL, Benda GI, Rahatzad M, Allen JR, Culver DH, Carlson CV, et al. Benzyl alcohol toxicity: impact on mortality and intraventricular hemorrhage among very low birth weight infants. Pediatrics. 1986 Apr;77(4):500–6.

17.

Achebe MM, Gafter-Gvili A. How I treat anemia in pregnancy: Iron, cobalamin, and folate. Blood. 2017;129(8):940–9.PubMedCrossRef

18.

Food. and Drug Administration (FDA). Medication Guide (Epoetin alfa).

19.

Al Shohaib S. Erythropoietin therapy in a pregnant post-renal transplant patient. Nephron. 1999;81(1):81–3.PubMedCrossRef

20.

Esposito S, Tenconi R, Preti V, Groppali E, Principi N. A systematic review on neonatal outcomes.

21.

Sanchez-Gonzalez LR, Castro-Melendez SE, Angeles-Torres AC, Castro-Cortina N, Escobar-Valencia A, Quiroga-Garza A. Efficacy and safety of adjuvant recombinant human erythropoietin and ferrous sulfate as treatment for iron deficiency anemia during the third trimester of pregnancy. Eur J Obstet Gynecol Reprod Biol [Internet]. 2016;205:32–6. Available from: https://doi.org/10.1016/j.ejogrb.2016.08.004.

22.

Leyland-Jones B, Bondarenko I, Nemsadze G, Smirnov V, Litvin I, Kokhreidze I, et al. A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J Clin Oncol. 2016;34(11):1197–207.PubMedCrossRef

23.

Thomas G, Ali S, Hoebers FJP, Darcy KM, Rodgers WH, Patel M, et al. without Erythropoietin in Anemic Patients Receiving Concurrent. NIH public acces. 2009;108(2):317–25.

24.

Gary PH. JBM., SCT, et al. The New England Journal of Medicine Downloaded from nejm.org on April 1, 2015. For personal use only. No other uses without permission. Copyright © 1990 Massachusetts Medical Society. All rights reserved. New English J Med. 1990;323(16):1120–3.CrossRef

25.

Pavese I, Satta F, Todi F, Di Palma M, Piergrossi P, Migliore A, et al. High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients. Ann Oncol. 2009;21(7):1523–8.PubMedCrossRef

26.

Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197–210.PubMedPubMedCentralCrossRef

27.

Body JJ. Prevention and treatment of side-effects of systemic treatment: Bone loss. Ann Oncol. 2010;21(SUPPL. 7):180–5.

28.

Taxel P, Faircloth E, Idrees S, Van Poznak C. Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. J Endocr Soc. 2018;2(7):574–88.PubMedPubMedCentralCrossRef

29.

Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006;24(4):675–80.PubMedCrossRef

30.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol [Internet]. 2011;12(7):631–41. Available from: https://doi.org/10.1016/S1470-2045(11)70122-X.

31.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313–20.PubMedCrossRef

32.

Djokanovic N, Klieger-Grossmann C, Koren G. Does Treatment With Bisphosphonates Endanger the Human Pregnancy? J Obstet Gynaecol Canada [Internet]. 2008;30(12):1146–8. Available from: https://doi.org/10.1016/S1701-2163(16)34026-9.

33.

Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A. Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? Autoimmun Rev [Internet]. 2010;9(8):547–52. Available from: https://doi.org/10.1016/j.autrev.2010.03.002.

34.

Food and Drug Administration. Full Prescribing Information - Actonel (Risedronate). 2009;1–39. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf.

35.

Food and Drug Administration. Alendronate. 2012;1–24. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021575s017lbl.pdf.

36.

Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol. 2006;22(4):578–9.PubMedCrossRef

37.

Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int. 2019;30(1):221–9.PubMedCrossRef

38.

Yeo W, Leung SF, Chan ATC, Chiu KW. Clinical Oncology Case Report. Int J Radiat Oncol Biol Phys. 1996;258:195–7.

39.

Chan B, Zacharin M. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: A report of four cases. J Clin Endocrinol Metab. 2006;91(6):2017–20.PubMedCrossRef

40.

O’Sullivan SM, Grey AB, Singh R, Reid IR. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int. 2006;17(7):1008–12.PubMedCrossRef

41.

Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone [Internet]. 2009;44(3):428–30. Available from: https://doi.org/10.1016/j.bone.2008.11.001.

42.

Bleau N, Patenaude V, Abenhaim HA. Risk of venous thrombo-embolic events in pregnant patients with cancer. J Matern Neonatal Med [Internet]. 2016 Feb 1;29(3):380–4. Available from: https://www.tandfonline.com/doi/abs/https://doi.org/10.3109/14767058.2015.1009439.

43.

Alshawabkeh L, Economy KE, Valente AM. Anticoagulation During Pregnancy: Evolving Strategies With a Focus on Mechanical Valves. J Am Coll Cardiol. 2016;68(16):1804–13.PubMedCrossRef

44.

James AH. Pregnancy-associated thrombosis. 2009.

45.

Macklon NS, Greer IA. The deep venous system in the puerperium: An ultrasound study. BJOG An Int J Obstet Gynaecol. 1997;104(2):198–200.CrossRef

46.

Goodrich SM, Wood JE. Peripheral venous distensibility and velocity of venous blood flow during pregnancy or during oral contraceptive therapy. Am J Obstet Gynecol [Internet]. 1964;90(6):740–4. Available from: https://doi.org/10.1016/0002-9378(64)90935-4.

47.

Bates SM, Greer A, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl.):e691S-e736S.PubMedPubMedCentralCrossRef

48.

Bates SM, Rajasekhar A, Middeldorp S, McLintock C, Rodger MA, James AH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2(22):3317–59.PubMedPubMedCentralCrossRef

49.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013;31(17):2189–204.PubMedCrossRef

50.

Blondon M, Bounameaux H. Secondary prevention of venous thromboembolism: One regimen may not fit all. Circulation. 2015;132(20):1856–9.PubMedCrossRef

51.

Beyer-Westendorf J, Michalski F, Tittl L, Middeldorp S, Cohen H, Abdul Kadir R, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thromb Haemost. 2016;116(4):651–8.PubMed

52.

FDA. Warfarin Full Prescribing Information. FDA drug labeling [Internet]. 2011;1–36. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf.

53.

Steinberg ZL, Dominguez-Islas CP, Otto CM, Stout KK, Krieger EV. Maternal and Fetal Outcomes of Anticoagulation in Pregnant Women With Mechanical Heart Valves. J Am Coll Cardiol. 2017;69(22):2681–91.PubMedPubMedCentralCrossRef

54.

Boon GJAM, Van Dam LF, Klok FA, Huisman MV. Management and treatment of deep vein thrombosis in special populations. Expert Rev Hematol [Internet]. 2018;11(9):685–95. Available from: https://doi.org/10.1080/17474086.2018.1502082.

55.

Kakkar AK. Venous thromboembolism prophylaxis and treatment in patients with cancer. Clin Adv Hematol Oncol. 2008;6(6):416–7.PubMed

56.

Van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AWA, et al. Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009;101(4):762–9.PubMedCrossRef

57.

De Carolis S, Di Pasquo E, Rossi E, Del Sordo G, Buonomo A, Schiavino D, et al. Fondaparinux in pregnancy: Could it be a safe option? A review of the literature. Thromb Res [Internet]. 2015;135(6):1049–51. Available from: https://doi.org/10.1016/j.thromres.2015.04.001.

58.

Alberta Provincial Tumour Program. Prophylaxis and Treatment of Venous Thromboembolism in Patients Undergoing Treatment for Solid Tumours. 2014;(February).

59.

Elsaigh E, Thachil J, Nash MJ, Tower C, Hay CRM, Bullough S, et al. The use of fondaparinux in pregnancy. Br J Haematol. 2015;168(5):762–4.PubMedCrossRef

60.

Tanimura K, Ebina Y, Sonoyama A, Morita H, Miyata S, Yamada H. Argatroban therapy for heparin-induced thrombocytopenia during pregnancy in a woman with hereditary antithrombin deficiency. J Obstet Gynaecol Res. 2012;38(4):749–52.PubMedCrossRef

61.

Stein PD, Matta F, Sabra MJ. Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism. Am J Med [Internet]. 2013;126(9):819–24. Available from: https://doi.org/10.1016/j.amjmed.2013.03.030.

62.

Molina MBG, Borraz PL. Neuraxial Anaesthesia Complications. Med Clin Rev. 2016;01(01):1–7.CrossRef

63.

Horlocker TT, Wedel DJ, Benzon H, Brown DL, Kayser Enneking F, Heit JA, et al. Regional anesthesia in the anticoagulated patient: Defining the risks (The Second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med. 2003;28(3):172–97.

64.

Snijder CA, Cornette JMW, Hop WCJ, Kruip MJHA, Duvekot JJ. Thrombophylaxis and bleeding complications after cesarean section. Acta Obstet Gynecol Scand. 2012;91(5):560–5.PubMedCrossRef

65.

Knol HM, Schultinge L, Veeger NJGM, Kluin-Nelemans HC, Erwich JJHM, Meijer K. The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy. Thromb Res [Internet]. 2012;130(3):334–8. Available from: https://doi.org/10.1016/j.thromres.2012.03.007.

66.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240–61.PubMedCrossRef

67.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(Supplement 5).

68.

Food, Administration D. EMEND. 2006.

69.

Food, Administration D. ZOFRAN. 1991.

70.

Food. and Drug Administration. DECADRON.:3–10.

71.

Food and Drug Administration. COMPAZINE. (5):1–15.

72.

Food, Administration D. REGLAN. 2017.

73.

Abramowitz A, Miller ES, Wisner KL, Miller ES. Treatment options for hyperemesis gravidarum. Arch Womens Ment Health [Internet]. 2017; Available from: https://doi.org/10.1007/s00737-016-0707-4.

74.

Esposito S, Tenconi R, Preti V, Groppali E, Principi N. Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes. Med (United States). 2016;95(38).

75.

Blake JF. Treatment of hyperemesis gravidarum. Br Med J. 1923;1897:1375. 2(.

76.

Koren G, Clark S, Hankins GDV, Caritis SN, Miodovnik M, Umans JG, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: A randomized placebo controlled trial. Am J Obstet Gynecol [Internet]. 2010;203(6):571.e1-571.e7 Available from: https://doi.org/10.1016/j.ajog.2010.07.030.

77.

Kashifard M, Basirat Z, Kashifard M, Golsorkhtabar-Amiri MMA. Ondansetrone or metoclopromide? Which is more effective in severe nausea and vomiting of pregnancy? A randomized trial double-blind study.

78.

Oliveira LG, Capp SM, You WB, Riffenburgh RH, Carstairs SD. Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: A randomized controlled trial. Obstet Gynecol. 2014;124(4):735–42.PubMedCrossRef

79.

Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Diaz S, Rasmussen SA. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res Part A - Clin Mol Teratol. 2012;94(1):22–30.CrossRef

80.

Danielsson B, Wikner BN, Källén B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol. 2014;50:134–7.PubMedCrossRef

81.

Pasternak B, Svanström H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013;368(9):814–23.PubMedCrossRef

82.

Parker SE, Van Bennekom C, Anderka M, Mitchell AA. Ondansetron for treatment of nausea and vomiting of pregnancy and the risk of specific birth defects. Obstet Gynecol. 2018;132(2):385–94.PubMedCrossRef

83.

Fejzo MS, MacGibbon KW, Mullin PM. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol [Internet]. 2016;62:87–91. Available from: https://doi.org/10.1016/j.reprotox.2016.04.027.

84.

Huybrechts KF, Hernández-Díaz S, Straub L, Gray KJ, Zhu Y, Patorno E, et al. Association of Maternal First-Trimester Ondansetron Use with Cardiac Malformations and Oral Clefts in Offspring. JAMA - J Am Med Assoc. 2018;320(23):2429–37.CrossRef

85.

Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The Safety of Metoclopramide Use in the First Trimester of Pregnancy. N Engl J Med. 2009;360:2528–63.PubMedCrossRef

86.

Pasternak B, Svanström H, Mølgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA - J Am Med Assoc. 2013;310(15):1601–11.CrossRef

87.

McParlin C, O’Donnell A, Robson SC, Beyer F, Moloney E, Bryant A, et al. Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: A systematic review. JAMA - J Am Med Assoc. 2016;316(13):1392–401.CrossRef

88.

Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: From disturbed motility to disordered movement - A review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3(3):138–48.PubMedCrossRef

89.

Yost NP, McIntire DD, Wians FH, Ramin SM, Balko JA, Leveno KJ. A randomized, placebo-controlled trial of corticosteroids for hyperemesis due to pregnancy. Obstet Gynecol. 2003;102(6):1250–4.PubMed

90.

Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol. 1994;12(3):596–600.PubMedCrossRef

91.

Smyth JF, Coleman RE, Nicolson M, Gallmeier WM, Leonard RCF, Cornbleet MA, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J. 1991;303(6815):1423–6.CrossRef

92.

Research TIG for Dexamethasone A, Granisetron, or Both for the Prevention of Nausea and Vomiting during Chemotherapy for Cancer. N Engl J Med. 1995;332(1):1–5.

93.

Rodríguez-Pinilla E, Martínez-Frías ML. Corticosteroids during pregnancy and oral clefts: A case-control study. Teratology. 1998;58(1):2–5.PubMedCrossRef

94.

Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: Two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol [Internet]. 2015;16(9):1079–89. Available from: https://doi.org/10.1016/S1470-2045(15)00035-2.

95.

Dos Santos LV, Souza FH, Brunetto AT, Sasse AD, Da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: A systematic review. J Natl Cancer Inst. 2012;104(17):1280–92.PubMedCrossRef

96.

Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, et al. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018;2018(9).

97.

Yokoe T, Hayashida T, Nagayama A, Nakashoji A, Maeda H, Seki T, et al. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta‐Analysis. Oncologist. 2019;24(6):e347–57.PubMedCrossRef

98.

Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, et al. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164(8):1214–20.PubMedCrossRef

99.

Usselman CWNSSJRB. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry. 2017;176(3):139–48.

100.

Habermann F, Fritzsche J, Fuhlbrück F, Wacker E, Allignol A, Weber-Schoendorfer C, et al. Atypical antipsychotic drugs and pregnancy outcome: A prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453–62.PubMedCrossRef

101.

Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15(3):183–92.PubMedCrossRef

102.

Sadowski A, Todorow M, Brojeni PY, Koren G, Nulman I. Pregnancy Outcomes following Maternal exposure to Second-generation antipsychotics given with other psychotropic drugs: A cohort study. BMJ Open. 2013;3(7).

103.

Gentile S. Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress Anxiety. 2010;27(7):675–86.PubMedCrossRef

104.

Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019;(August):1601–12.

105.

Boulanger J, Boursiquot JN, Cournoyer G, Lemieux J, Masse MS, Almanric K, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: CEPO review and clinical recommendations. Curr Oncol. 2014;21(4):630–41.CrossRef

106.

Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol. 2004;190(4):878–81.PubMedCrossRef

107.

Kemp MW, Newnham JP, Challis JG, Jobe AH, Stock SJ. The clinical use of corticosteroids in pregnancy. Hum Reprod Update. 2016;22(2):240–59.PubMed

108.

Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: Ten questions and some answers. Lupus. 2008;17:416–20. (5 SPEC. ISS ).PubMedCrossRef

109.

Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;2017(3).

110.

Global Initiative for Asthma. Pocket Guide for Asthma Management an Precention. Glob Initiat Asthma. 2019;1–32.

111.

Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and treatment of primary adrenal insufficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364–89.PubMedCrossRef

112.

Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. Cmaj. 2011;183(7):796–804.PubMedPubMedCentralCrossRef

113.

Taylor RL. American association for the advancement of science. J Clin Endocrinol Metab. 1950;10(10):1361–2.CrossRef

114.

Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–92.PubMedCrossRef

115.

Mossey PA, Little J, Munger RG, Dixon MJ, Shaw WC. Cleft lip and palate. Lancet [Internet]. 2009 Nov 21;374(9703):1773–85. Available from: https://doi.org/10.1016/S0140-6736(09)60695-4.

116.

Schatz M, Dombrowski MP, Wise R, Momirova V, Landon M, Mabie W, et al. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol. 2004;113(6):1040–5.PubMedCrossRef

117.

Guller S, Kong L, Wozniak R, Lockwood CJ. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes. J Clin Endocrinol Metab [Internet]. 1995 Jul 1;80(7):2244–50. Available from: https://doi.org/10.1210/jcem.80.7.7608287.

118.

Lockwood J. A Potential Rupture of the Fetal Membranes *. J Perinat Med. 1995;(November):2244–50.

119.

Øtensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):1–19.

120.

Lajic S, Karlsson L, Nordenström A. Prenatal Treatment of Congenital Adrenal Hyperplasia: Long-Term Effects of Excess Glucocorticoid Exposure. 2018.

121.

Edwards A, Baker LSWE. Effect of antenatal glucocorticoid therapy on arterial and venous blood flow velocity waveforms in severely growth-restricted fetuses. Ultrasound Obstet Gynecol. 2004;23(6):584–9.CrossRef

122.

Edwards A, Baker LSWE. Changes in umbilical artery flow velocity waveforms following maternal administration of betamethasone. Placenta. 2003.

123.

Senat Registrar MV, Minoui Registrar S, Registrar M, Fernandez Projhssor H, Frydman Professor R, ViUe Senior Lecturer Y. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study. Br J Obstet Gynaecol. 1998;105(July):749–55.CrossRef

124.

Ashwood PJ, Crowther CA, Willson KJ, Haslam RR, Kennaway DJ, Hiller JE, et al. Neonatal adrenal function after repeat dose prenatal corticosteroids: A randomized controlled trial. Am J Obstet Gynecol. 2006;194(3):861–7.PubMedCrossRef

125.

Tijsseling D, Wijnberger LDE, Derks JB, van Velthoven CTJ, de Vries WB, van Bel F, et al. Effects of antenatal glucocorticoid therapy on hippocampal histology of preterm infants. PLoS One. 2012;7(3):1–7.CrossRef

126.

Dalziel SR, Lim VK, Lambert A, McCarthy D, Parag V, Rodgers A, et al. Antenatal exposure to betamethasone: Psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. Br Med J. 2005;331(7518):665–8.CrossRef

127.

Sotiriadis A, Tsiami A, Papatheodorou S, Baschat AA, Sarafidis K, Makrydimas G. Neurodevelopmental outcome after a single course of antenatal steroids in children born preterm: A systematic review and meta-analysis. Obstet Gynecol. 2015;125(6):1385–96.PubMedCrossRef

Title: Supportive medication in cancer during pregnancy
Authors: Flora Zagouri
Nikolaos Dedes
Alkistis Papatheodoridi
Michael Liontos
Meletios Athanasios Dimopoulos
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Bisphosphonate
Glucocorticoid
Published in: BMC Pregnancy and Childbirth / Issue 1/2020
Electronic ISSN: 1471-2393
DOI: https://doi.org/10.1186/s12884-020-03432-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Supportive medication in cancer during pregnancy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Application of cook balloon during aorta replacement in a pregnant Marfan-syndrome patient: a case report

Validation of the Italian version of the Revised Prenatal Coping Inventory (NuPCI) and its correlations with pregnancy-specific stress

Be quiet and man up: a qualitative questionnaire study into fathers who witnessed their Partner’s birth trauma

Fear of childbirth among pregnant women attending antenatal care in Arba Minch town, southern Ethiopia: a cross-sectional study

The Reproductive Agency Scale (RAS-17): development and validation in a cross-sectional study of pregnant Qatari and non-Qatari Arab Women

Distribution of maternal red cell antibodies and the risk of severe alloimmune haemolytic disease of the foetus in a Chinese population: a cohort study on prenatal management